Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review (Q37363328)

19 August 2017

Prophylactic G-CSF in patients with early-stage breast cancer: a health economic review (English)

1 reference

19 August 2017

1 reference

P Trueman

1

1 reference

PMCID

2752222

19 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

British Journal of Cancer

19 August 2017

1 reference

19 August 2017

101 Suppl 1

1 reference

19 August 2017

S15-7

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605271

19 August 2017

0 references

cites work

Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752222

Prevention of febrile neutropenia: use of prophylactic antibiotics

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752222

6 September 2017

Myeloid growth factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752222

EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752222

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752222

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752222

Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752222

Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752222

When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2752222

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19756001

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6605271

1 reference

PMCID

2752222

Dimensions Publication ID

19 August 2017

0 references

1 reference

19 August 2017

1 reference

PMCID

2752222